Just out with its most recent earnings showing strong growth, Codexis is the Master of the Pivot having successfully repositioned in industrials and pharma — a diverse set of tech all based on the unique CodeEvolver platform and the advantages of directed evolution. Here are the markets, technologies, sources of revenues, trends, lines of business.
It’s been more than 10 years since the celebrated IPOs of Amyris, Codexis and Gevo showed that the second wave of industrial biotechnology (after the first wave of ethanol companies) was producing mature companies of size and substance. Since then, the crash of oil prices in the 2010s forced a pivot by these companies. Amyris […]
If you missed Friday’s exclusive Q&A with Codexis story, here’s a more visual way to get an inside look at the enzyme engineering company via this illuminating slide guide they just released. From synthetic biology, the acceleration of enzyme discovery and engineering, the commercialization engine, their customer base, case studies, partnerships, and more.
Q: Tell us about your organization. What do you do? Codexis is a world-leading enzyme engineering company, enabling the promise of synthetic biology across multiple industries – from the sustainable manufacturing of pharmaceuticals, food and industrial products, to the expansion of life science tools and the discovery of novel biologic drug candidates. We partner with […]
In California, Codexis, Inc., enzyme engineering company, provided a business update with their Sustainable Manufacturing business demonstrating “remarkable growth, as we significantly executed against the large enzyme orders we received from Pfizer to support its COVID-19 antiviral therapeutic candidate” as well as strong results in the faster-to-market food sector, including enzyme sales for Tate & […]
In California, Codexis, Inc., a leading enzyme engineering company reported record product revenue of $14.7M, up 227% YOY, that drove their product gross margin to a new high of 71%. Product revenues were primarily driven by the sale of enzymes used to manufacture branded pharmaceutical products. “Codexis had an extraordinarily strong second quarter, with record […]
In California, enzyme engineering company, Codexis, is raising its guidance for 2021, following the receipt of a binding purchase order for up to $13.9 million of a proprietary high performance enzyme product from an undisclosed global pharmaceutical company. The majority of this order was not included in Codexis’ prior guidance for 2021; accordingly, the Company […]
In California, enzyme engineering company Codexis reported total revenues for Q1 2021 at $18.0 million, an increase of 23% from $14.7 million in Q1 2020. On a segment basis, $14.2 million in revenue was from the Performance Enzymes segment and $3.8 million was from Novel Biotherapeutics. Product revenues increased 101% to $10.2 million in Q1 […]
In California, Codexis’s 2020 full year product gross margin exceeds 50% for the first time in company’s history and expects 2021 to be strong as well with projected total revenues of $82-85 million and product revenues of $36-39 million, especially thanks to its enzyme engineering platform, CodeEvolver. “Codexis delivered strong results in 2020, despite the […]
Q: What was the reason for founding your organization – what was the open niche you saw that could be addressed with a new product or service? What was the problem, or gap, or opportunity? Codexis works to create a brighter future by improving the health of people, and our planet. By discovering, developing and […]
